Clear Creek Bio Revenue and Competitors
Estimated Revenue & Valuation
- Clear Creek Bio's estimated annual revenue is currently $1.4M per year.
- Clear Creek Bio's estimated revenue per employee is $155,000
Employee Data
- Clear Creek Bio has 9 Employees.
- Clear Creek Bio grew their employee count by -10% last year.
Clear Creek Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder & CEO | Reveal Email/Phone |
Clear Creek Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Clear Creek Bio?
Clear Creek Bio is a private, clinical-stage biotech company focused on developing novel therapies to address infectious disease and cancer. The company’s lead drug candidate, brequinar, is a dihydroorotate dehydrogenase (DHODH) inhibitor with oral bioavailability and high potency. Clear Creek Bio is evaluating brequinar in clinical trials as a potential once-daily treatment for COVID-19. The company is also assessing brequinar as a potential treatment for acute myeloid leukemia.
keywords:N/A
N/A
Total Funding
9
Number of Employees
$1.4M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 9 | N/A | N/A |
#2 | $0.7M | 9 | N/A | N/A |
#3 | $0.7M | 9 | -10% | N/A |
#4 | $0.7M | 9 | -71% | $138.8M |
#5 | $0.7M | 9 | -25% | N/A |